Treatment for stage 2 essential thrombocythemia is highly personalized. Not every patient requires medication right away, and ...

The FDA accepted Besremi's application for essential thrombocythemia, supported by SURPASS-ET and EXCEED-ET trial results, with a review target date of August 30, 2026. Essential thrombocythemia is a ...

The sBLA is supported by data from the phase 3 SURPASS-ET trial, as well as confirmatory data from the phase 2b EXCEED-ET trial.

Hemorrhagic events post-diagnosis in patients with ET significantly increase mortality risk, more than thrombosis or disease progression. Intracranial hemorrhage is the most lethal bleeding ...

The FDA has accepted the supplemental Biologics License Application (BLA) for ropeginterferon alfa-2b-njft (Besremi), a ...

Overexpression of the Polycythemia Rubra Vera-1 Gene in Essential Thrombocythemia Authors: Luciana Teofili, Maurizio Martini, Myriam Luongo, Antonella Di Mario, Giuseppe Leone, Valerio De Stefano, and ...

100% (29/29) of patients experienced platelet count reduction to within normal ranges (150 – 400 x 109/L). 90% (26/29) of patients achieved a platelet count of less than 400 x 109/L without ...

Bleeding in ET can range from minor mucocutaneous events to severe hemorrhages, with gastrointestinal bleeding being most common. The JAK2 V617F variant increases bleeding and thrombosis risk, ...

BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep ...

Change in platelet counts was a common phenomenon after major joint surgery, and elevated PLTC occurred in about half of the patients who were admitted to the rehabilitation centre. Thrombocytosis was ...